This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Marumo, T. Articles by Busse, R. Search for Related Content PubMed PubMed Citation Articles by Marumo, T. Articles by Busse, R.

(Hypertension. 1998;32:1083-1088.)
© 1998 American Heart Association, Inc.

Scientific Contributions

Glucocorticoids Inhibit Superoxide Anion Production and p22 Phox mRNA Expression in Human Aortic Smooth Muscle Cells

Takeshi Marumo; Valérie B. Schini-Kerth; Ralf P. Brandes; Rudi Busse

From the Institut für Kardiovaskuläre Physiologie, Klinikum der Johann Wolfgang Goethe Universität Theodor-Stern-Kai 7, D-60590 Frankfurt am Main, Germany.

Correspondence to Takeshi Marumo, MD, PhD, Institut für Kardiovaskuläre Physiologie, Klinikum der Johann Wolfgang Goethe Universität, Theodor-Stern-Kai 7, D-60590 Frankfurt am Main, Germany. E-mail r.busse{at}em.uni-frankfurt.de

	Abstract

Top Abstract Introduction Methods Results Discussion References

 
Abstract—Recent reports suggest that the increased production of reactive oxygen species (ROS) in the vascular wall may contribute to the functional and structural changes associated with hypertension and atherosclerosis. Although glucocorticoid therapy can promote atherosclerosis, protective effects of these compounds on vascular lesion formation have been reported. In the present study, we investigated whether ROS production in cultured human aortic smooth muscle cells (HSMCs) can be modulated by glucocorticoids. Pretreatment of HSMCs with dexamethasone for 24 hours attenuated the basal and platelet-derived growth factor (PDGF)-AB– and angiotensin II–induced superoxide anion (O₂^{· -}) production. PDGF-AB–stimulated O₂^{· -} production was also inhibited by prednisolone and hydrocortisone but not by other steroids, such as testosterone and norgestrel. Incubation of HSMCs with glucocorticoids for 24 hours decreased 2',7'-dichlorodihydrofluorescein (DCHF) oxidation, an indicator of intracellular ROS levels. Dexamethasone decreased the mRNA expression of p22 phox, one of the components of NADPH oxidase, but had no effect on the activity of superoxide dismutase. The effects of dexamethasone on DCHF oxidation, and p22 phox mRNA expression and PDGF-AB–stimulated O₂^{· -} production were inhibited by the glucocorticoid receptor antagonist RU486. These results indicate that glucocorticoids decrease O₂^{· -} production by HSMCs via a receptor-dependent pathway. This effect is likely to be mediated by a decrease in the generating system, such as downregulation of p22 phox mRNA, rather than an increased inactivation of O₂^{· -}. The inhibition of ROS production might contribute to the local protective effects that glucocorticoids have on vascular lesion formation.

Key Words: glucocorticoids • superoxide • free radicals • NADH • NADPH oxidase • muscle, smooth, vascular

	Introduction

Top Abstract Introduction Methods Results Discussion References

 
Increased production of vascular reactive oxygen species (ROS) has been implicated in the development of hypertension and atherosclerosis. In particular, the excess production of superoxide anion (O₂^{· -}) by vascular cells, including endothelial cells, has been reported to result in a decreased release of nitric oxide in stroke-prone spontaneously hypertensive rats.¹ Increased vascular ROS production has also been observed in other animal models of hypertension^{2 3 4 5} and atherosclerosis.^{6 7} Endothelium^{2 4 7} and the smooth muscle layer³ are reportedly the predominant sources of vascular ROS production depending on the disease state.

Vascular O₂^{· -} levels seem to have important functional consequences because impaired endothelium-dependent relaxation in angiotensin II (Ang II)–induced hypertension has been partly improved by elevating vascular superoxide dismutase (SOD) levels.³ In addition, recent reports have suggested that vascular smooth muscle cell (VSMC)–derived ROS may promote proatherogenic processes by affecting VSMC proliferation and chemotaxis,^{8 9} activation of nuclear factor-B,¹⁰ oxidative modification of LDL,¹¹ and the induction of the LDL scavenger receptor.¹²

Although increasing evidence suggests an important role for ROS in cardiovascular diseases, the main O₂^{· -}–generating system in VSMCs remains to be characterized. Recently, p22 phox, one of the components of NADPH oxidase in phagocytes, was shown to be expressed in VSMCs and involved in Ang II–induced ROS production.¹³ Moreover, the expression of p22 phox mRNA was upregulated in aortas from rats with Ang II–induced hypertension.¹⁴ However, little is known about the regulation of this oxidase component in VSMCs.

Glucocorticoids are known to modify the course of vascular lesion formation, and long-term systemic glucocorticoid therapy induces risk factors for atherosclerosis, including hypertension, hypercholesterolemia, and impairment of glucose tolerance.¹⁵ However, protective effects of glucocorticoids on cholesterol-induced atherogenesis¹⁶ have also been reported. In particular, the local application of dexamethasone demonstrably inhibits neointimal proliferation in balloon-injured arteries.¹⁷ In the present study, we investigated whether ROS production and mRNA expression of p22 phox in human aortic smooth muscle cells (HSMCs) can be modulated by glucocorticoids.

	Methods

Top Abstract Introduction Methods Results Discussion References

 
Smooth Muscle Cell Culture
HSMCs, isolated from the thoracic aorta of a young healthy donor for cardiac transplantation using enzymatic disaggregation as described previously,¹⁸ were kindly provided by Dr T. Scott-Burden (Texas Heart Institute, Houston). Cells from passages 16 through 24 were deprived of serum for 24 hours by incubation with the medium containing 0.1% BSA after reaching confluence as described.¹⁰ These cells were then incubated with the same medium in the presence and absence of steroids as indicated. The steroids and RU486 were dissolved in DMSO (final concentration, 0.1% or 0.2%).

Human coronary artery smooth muscle cells obtained from Clonetics were maintained in smooth muscle cell basal medium (SmBM, Clonetics) with supplements (SingleQuots, Clonetics) containing 0.5 ng/mL epidermal growth factor, 5 µg/mL insulin, 2 ng/mL fibroblast growth factor, 50 µg/mL gentamicin, 50 ng/mL amphotericin-B, and 5% fetal bovine serum according to the manufacturer's recommendations. After reaching confluence, the cells were incubated in SmBM supplemented with 10% SingleQuots in the presence of vehicle or dexamethasone for 24 hours. The cell numbers were not significantly different between groups treated with vehicle and dexamethasone at the end of the incubation.

O₂^{· -} Production
The release of O₂^{· -} was determined by measuring SOD-inhibitable reduction of ferricytochrome c as described previously.¹⁰ Briefly, after the pretreatment with 100 U/mL SOD or vehicle for 10 minutes, HSMCs were incubated with 81 µmol/L ferricytochrome c in the presence and absence of reagents for 1 hour. The absorbance of the medium at 550 nm was then measured, and SOD-sensitive O₂^{· -} production was calculated. The number of cells was counted using a Neubauer chamber (Fisher Scientific) after trypsinization.

Intracellular Oxidant Production
The determination of intracellular oxidant production was based on the oxidation of 2',7'-dichlorodihydrofluorescein (DCHF) by peroxide, resulting in the formation of the fluorescent compound 2',7'-dichlorofluorescein (DCF)¹⁹ using a Cytofluor 2300 multiplate fluorimeter (Millipore) as described previously.²⁰ HSMCs were incubated in Hanks' balanced salt solution enriched with 20 µmol/L DCHF diacetate for 20 minutes. The cells were washed, and the fluorescence was measured with a multiplate fluorimeter using excitation and emission wavelengths of 485 nm and 530 nm, respectively. For the experiments with hydrogen peroxide, the fluorescence was further measured at 5 and 15 minutes after the addition of 20 µmol/L hydrogen peroxide. The increase in fluorescence induced by exogenous hydrogen peroxide was calculated by subtracting the increase in fluorescence obtained without hydrogen peroxide, which represents the endogenous component of DCHF oxidation. To investigate the effects of dexamethasone on agonist-induced intracellular oxidant production, fluorescent signals were monitored for 1 hour after the DCHF loading. The cells were maintained at 37°C during this period.

SOD Activity
SOD activity was measured by monitoring the inhibition of the rate of xanthine oxidase–mediated reduction of cytochrome c, as previously described.²¹ The cells were collected and homogenized with sonication in a 20-mmol/L potassium phosphate buffer (pH 7.0) containing 1 mmol/L EGTA, 0.5 mmol/L PMSF, 10 µg/mL aprotinin, 10 µg/mL leupeptin, 10 µg/mL pepstatin, 10 µg/mL trypsin inhibitor, 10 µg/mL chymostatin, and 10 µg/mL antipain. SOD activity was determined spectrophotometrically using homogenate (75 µg total protein) to inhibit reduction of ferricytochrome c by O₂^{· -} generated by the addition of xanthine and xanthine oxidase. Calibration was made using known amounts of SOD.

Northern Blot Analysis
Total RNA was extracted, size-fractionated, and transferred to nylon membranes (Hybond, Amersham-Buchler) as described previously.¹⁰ After hybridization with the labeled 780-bp p22 phox cDNA (kindly provided by Dr K.K. Griendling, Emory University, Atlanta, Ga)²² or the cDNA probe specific for mouse 18S rRNA, the blots were washed, exposed to x-ray film, and analyzed with a densitometer as described previously.^{10 23} The values obtained from blots hybridized with the p22 phox cDNA were corrected using the values obtained with the 18S rRNA probe and were expressed as a percentage of control.

Reagents
Recombinant human platelet-derived growth factor (PDGF)-AB was purchased from R&D Systems Inc. Ang II was from Bachem Biochemica GmbH. Ferricytochrome c, dexamethasone, prednisolone, norgestrel, hydrocortisone, and testosterone were from Sigma Chemical Co. SOD was from Boehringer Mannheim GmbH. Fetal bovine serum was from Biochrom KG. DCHF was from Molecular Probes Inc. RU486 was a gift from Roussel Uclaf. All other chemicals and reagents were obtained from commercial sources and were of reagent or molecular biology grade.

Statistics
Multiple comparisons were evaluated with ANOVA, followed by Fisher's protected least-significant difference method. Data are presented as mean±SEM, and P<0.05 was considered to be statistically significant.

	Results

Top Abstract Introduction Methods Results Discussion References

 
PDGF-AB (30 ng/mL) increased O₂^{· -} production from HSMCs measured after a 1-hour incubation period (Figure 1A), which is consistent with our previous observation.¹⁰ Pretreatment of the cells with dexamethasone (1 µmol/L) for 24 hours significantly inhibited the generation of O₂^{· -} by PDGF-AB–treated HSMCs. However, dexamethasone did not modify PDGF-AB–induced O₂^{· -} production when applied at the same time as PDGF-AB. Therefore, the glucocorticoid was not added during O₂^{· -} measurement in subsequent experiments. As shown in Figure 1B, the treatment of HSMCs with 1 µmol/L dexamethasone for 24 hours also significantly decreased the basal and Ang II (1 µmol/L)–induced O₂^{· -} production. The inhibitory effect of dexamethasone was concentration-dependent (Figure 1C), and a significant attenuation of PDGF-AB–induced O₂^{· -} production was observed at concentrations >10 nmol/L.

View larger version (20K): [in this window] [in a new window]   Figure 1. Dexamethasone (dex) decreases O2· - production from HSMCs. A, HSMCs were pretreated with vehicle or 1 µmol/L dexamethasone for various time intervals . The cells were washed, and O2· - production during a 1-hour incubation period was measured in the absence and presence of 30 ng/mL PDGF-AB and dexamethasone as indicated. In the dexamethasone groups, the hormone was also present during O2· - measurement. B, HSMCs were pretreated with 1 µmol/L dexamethasone for 24 hours, and O2· - production during a 1-hour incubation period was measured with and without 1 µmol/L Ang II. C, HSMCs were pretreated with various concentrations of dexamethasone for 24 hours, and O2· - production during a 1-hour incubation period was measured with and without PDGF-AB. The values are mean±SEM from 4 different batches of cells. *P<0.05 vs control values; +P<0.05 vs values with PDGF-AB; #P<0.05 vs values with Ang II.

Treatment of the cells with other glucocorticoids, including hydrocortisone (100 nmol/L) and prednisolone (100 nmol/L), for 24 hours also significantly decreased the PDGF-AB–induced O₂^{· -} production in HSMCs (Figure 2A). In contrast, neither testosterone (100 nmol/L) nor norgestrel (100 nmol/L) inhibited O₂^{· -} production in PDGF-AB–stimulated HSMCs (Figure 2B). In the presence of the glucocorticoid receptor antagonist RU486 (1 µmol/L), dexamethasone (100 nmol/L) failed to decrease PDGF-AB–induced O₂^{· -} production in HSMCs (Figure 2C), suggesting that the inhibitory effect of dexamethasone is dependent on the glucocorticoid receptor. None of the compounds used affected cell viability as determined by the exclusion of trypan blue.

View larger version (20K): [in this window] [in a new window]   Figure 2. Effects of glucocorticoids (A), testosterone and norgestrel (B), and the glucocorticoid receptor antagonist RU486 (C) on PDGF-AB–stimulated O2· - production. HSMCs were incubated with vehicle, 100 nmol/L steroids, 1 µmol/L RU486, or a combination of 100 nmol/L dexamethasone (dex) and RU486 as indicated for 24 hours. O2· - production during a 1-hour incubation period was measured with and without 30 ng/mL PDGF-AB. The values are mean±SEM from 4 different batches of cells. *P<0.05 vs control values;. +P<0.05 vs values with PDGF-AB; #P<0.05 vs values with dexamethasone.

The effect of glucocorticoids on the intracellular ROS production was determined by monitoring DCF fluorescence. In cells incubated with dexamethasone (100 nmol/L) and prednisolone (100 nmol/L) for 24 hours, DCF fluorescence was significantly decreased compared with in control cells (Figure 3A). Testosterone (100 nmol/L) and norgestrel (100 nmol/L) were without effect, whereas RU486 (1 µmol/L) completely antagonized the inhibitory effect of dexamethasone (100 nmol/L) on the oxidation of DCHF (Figure 3B). In contrast to the oxidation of DCHF by endogenous ROS, the increase in fluorescence induced by exogenous hydrogen peroxide (20 µmol/L) was not significantly different between groups whether treated with dexamethasone (100 nmol/L) for 24 hours or not (vehicle 22.7±1.9 arbitrary units versus dexamethasone 24.0±1.5 arbitrary units at 5 minutes; vehicle 34.0±4.4 arbitrary units versus dexamethasone 38.0±3.5 arbitrary units at 15 minutes, n=4), suggesting that dexamethasone selectively decreases endogenous ROS production. The inhibitory effect of dexamethasone (100 nmol/L) on DCHF oxidation was also observed in human coronary artery smooth muscle cells (vehicle 225.7±17.8 versus dexamethasone 117.7±24.2 arbitrary units, n=3).

View larger version (22K): [in this window] [in a new window]   Figure 3. Effects of glucocorticoids (A) and the glucocorticoid receptor antagonist RU486 (B) on DCHF oxidation. After the incubation with vehicle or 100 nmol/L steroids as indicated in panel A, and 100 nmol/L dexamethasone (dex), 1 µmol/L RU486, or a combination of dexamethasone and RU486 (B) for 24 hours, HSMCs were incubated with DCHF for 20 minutes, and DCF fluorescence was measured. The values are mean±SEM from 4 different batches of cells. *P<0.05 vs control values; +P<0.05 vs values with dexamethasone.

To investigate the effects of dexamethasone on agonist-induced intracellular oxidant production, increases in DCF fluorescence during a 1-hour incubation were measured in the presence and absence of PDGF-AB (30 ng/mL) or Ang II (1 µmol/L). PDGF-AB significantly enhanced the increase in fluorescence during the 1-hour incubation, whereas pretreatment of HSMCs with dexamethasone (1 µmol/L, 24 hours) significantly attenuated the increases in fluorescence: control 100.0±7.9%; PDGF-AB 159.9±17.1%, dexamethasone 52.0±3.4% (P<0.05 versus control values); dexamethasone+PDGF-AB 83.5±8.7% of control, n=7 to 9 (P<0.05 versus values with PDGF-AB). In addition, dexamethasone (100 nmol/L) significantly attenuated the increases in fluorescence signals obtained from Ang II–treated HSMCs: control 100.0±4.7%; Ang II 125.9±6.4%, dexamethasone 69.8±11.8% (P<0.05 versus control values); dexamethasone+Ang II 75.1±4.7% of control, n=4 (P<0.05 versus values with Ang II).

To clarify whether inhibition of O₂^{· -} production by dexamethasone is due to an increased inactivation of O₂^{· -}, SOD activity was measured. SOD activity was not significantly changed by the treatment of HSMCs with dexamethasone (100 nmol/L) for 24 hours (vehicle 6.99±0.23 U/mg versus dexamethasone 6.35±0.16 U/mg, n=3).

Because p22 phox has been suggested to be involved in ROS production in VSMCs,¹³ we determined whether the expression of p22 phox mRNA in HSMCs could be modified by dexamethasone. Dexamethasone (100 nmol/L) decreased p22 phox mRNA expression within 5 hours (27.2±9.3% inhibition, n=3), and the inhibitory effect was more pronounced after 10 and 24 hours (Figure 4A, 63.4±3.4% and 62.8±2.8% inhibition, n=3 and 4, respectively). Decreases in p22 phox mRNA expression by 100 nmol/L dexamethasone (62.5% inhibition) were attenuated in the presence of 1 µmol/L RU486 (22.4% inhibition), whereas RU486 alone only minimally affected the p22 phox mRNA levels (0.8% inhibition, Figure 4B).

View larger version (47K): [in this window] [in a new window]   Figure 4. Dexamethasone-induced inhibition of p22 phox mRNA expression and reversal by the glucocorticoid receptor antagonist RU486. HSMCs were treated with vehicle or 100 nmol/L dexamethasone (dex) for various times (A) and with vehicle, 100 nmol/L dexamethasone (dex), 1 µmol/L RU486, or a combination of dex and RU486 for 10 hours (B), and then expression of p22 phox mRNA was analyzed by Northern blot analysis. 18S rRNA levels are shown in the lower panels. A representative autoradiogram from 3 (A) and 2 (B) different experiments with identical results is shown.

	Discussion

Top Abstract Introduction Methods Results Discussion References

 
The present study demonstrates that dexamethasone attenuates the basal, Ang II–, and PDGF-AB–stimulated production of O₂^{· -} in HSMCs. These inhibitory effects appear to be a consequence of glucocorticoid receptor activation. This assumption is based on the observations that PDGF-AB–induced O₂^{· -} production was also decreased by hydrocortisone and prednisolone but not by other classes of steroids such as testosterone and norgestrel. Moreover, the inhibition of PDGF-AB–induced O₂^{· -} by dexamethasone was not observed in the presence of the glucocorticoid receptor antagonist RU486.

Glucocorticoids also decreased intracellular ROS levels measured by DCHF oxidation in HSMCs. PDGF-⁸ and cytomegalovirus-stimulated²⁴ DCHF oxidation in VSMCs is reportedly inhibited by catalase, suggesting that hydrogen peroxide is the main substance that oxidizes DCHF under these conditions. When one considers that DCHF oxidation in HSMCs is paralleled by the production of O₂^{· -}, a precursor of hydrogen peroxide, it is likely that the levels of DCHF oxidation reflect, at least to some extent, the intracellular production of hydrogen peroxide in HSMCs, although other hydroperoxides can also oxidize DCHF.²⁵

The effect of dexamethasone on O₂^{· -} production in HSMCs was unrelated to changes in SOD activity and can be at least partially attributed to a decrease in the expression of p22 phox. p22 phox is a component of the membrane-bound cytochrome b-558 complex, which transfers an electron from NADPH to oxygen in the phagocyte NADPH oxidase system.²⁶ Although there is some debate as to whether an identical enzyme is expressed in VSMCs, transfection of antisense p22 phox cDNA into VSMCs is reported to decrease Ang II–induced DCHF oxidation in these cells. Thus, an NADH/NADPH oxidase that is similar if not identical to that in leukocytes has been proposed to be expressed in VSMCs and to be involved in ROS production in response to Ang II.¹³ Indeed, we previously reported that the production of O₂^{· -} by PDGF-AB–stimulated HSMCs is sensitive to iodonyl diphenyl,¹⁰ an inhibitor of flavoenzymes including NADPH oxidase in phagocytes,²⁷ further suggesting a role for NADH/NADPH oxidase in VSMCs. The glucocorticoid-induced decrease in p22 phox mRNA observed in the present investigation seems to be unique to VSMCs, because p22 phox mRNA levels are reported not to be influenced by dexamethasone in human polymorphonuclear leukocytes.²⁸ To understand the mechanism by which dexamethasone inhibits p22 phox mRNA expression in VSMCs, additional information such as analysis of the promoter region, determination of gene transcription rate, and evaluation of mRNA stability of p22 phox is required.

Expression of p22 phox mRNA has been reported to be increased in the aorta of Ang II–infused hypertensive rats.¹⁴ Impaired endothelium-dependent vascular relaxation observed in this animal model has been shown to be reversed in part by increasing vascular SOD levels,³ suggesting a crucial role for vascular O₂^{· -} in endothelial dysfunction. Additionally, a polymorphism of p22 phox, which alters an amino acid in the potential heme-binding sites, has been demonstrated to be more frequent in control subjects compared with patients with coronary artery disease.²⁹ Collectively, these reports support the hypothesis that the alteration of p22 phox expression might modulate ROS levels in the vasculature and influence the progression of vascular diseases.

The effects of glucocorticoids on ROS production in VSMCs may, in addition to the downregulation of p22 phox, involve other intracellular mechanisms. For example, phospholipase A₂ (PLA₂), an enzyme that is essential for O₂^{· -} production in several cell types,³⁰ is inhibited by glucocorticoids in VSMCs.³¹ In addition, activation of PLA₂ is suggested to be involved in cytomegalovirus-induced ROS production in VSMCs.³² Thus, it is conceivable that inhibition of PLA₂ is involved in the decreased ROS production observed after glucocorticoid treatment. However, an inhibitor of cytosolic 85-kDa PLA₂, AACOCF₃, which has been shown to inhibit PDGF-BB–induced arachidonic acid release from HSMCs,³³ failed to inhibit PDGF-AB–stimulated O₂^{· -} production (T.M., V.B.S.-K., R.P.B., and R.B., unpublished data, 1998). Although we cannot rule out the possibility that some isoforms of PLA₂ are insensitive to AACOCF₃ in HSMCs, the inhibition of PLA₂ does not seem to have a major role in the glucocorticoid-induced inhibition of ROS production described here.

In addition to promoting risk factors of atherosclerosis, glucocorticoids have been shown to upregulate Ang II receptor type 1,^{34 35} to stimulate cholesteryl ester formation,³⁶ and to induce angiotensin-converting enzyme mRNA and activity³⁷ in VSMCs. Although these effects of glucocorticoids are potentially atherogenic, the hormone can also inhibit vascular lesion formation.^{16 17} Protective effects of glucocorticoids, including the inhibition of ROS production observed in the present study, may exceed their proatherogenic effects when locally applied.¹⁷

Interestingly, systemic administration of dexamethasone to adrenalectomized spontaneous hypertensive rats, but not Wistar-Kyoto rats, has been demonstrated to increase oxidative stress in mesenteric arterioles.² Because in these animals endothelial cells are proposed to be the source of ROS, it cannot be ruled out that ROS production is differentially regulated by glucocorticoids in endothelial cells and VSMCs. Alternatively, in this animal model increased ROS production in arterioles by dexamethasone might be achieved by systemic effects of the glucocorticoid, such as enhanced hemodynamic forces due to increased blood pressure and altered metabolism of glucose and lipid, all of which are potential stimuli of O₂^{· -} production.^{38 39 40 41}

In summary, the present study shows that glucocorticoids decrease ROS production and p22 phox mRNA expression in HSMCs via a glucocorticoid receptor-dependent pathway. This inhibition of ROS production might contribute at least in part to the local beneficial effect of glucocorticoids on the progression of vascular injury.

	Acknowledgments

 
This work was supported by the Deutsche Forschungsgemeinschaft (SFB 553, B1). Dr Marumo is supported by Uehara Memorial Foundation and Alexander von Humboldt-Stiftung.

Received May 25, 1998; first decision June 30, 1998; accepted August 5, 1998.

	References

Top Abstract Introduction Methods Results Discussion References

 

1. Grunfeld S, Hamilton CA, Mesaros S, McClain SW, Dominiczak AF, Bohr DF, Malinski T. Role of superoxide in the depressed nitric oxide production by the endothelium of genetically hypertensive rats. Hypertension.. 1995;26:854–857.[Abstract/Free Full Text]
2. Suzuki H, Swei A, Zweifach BW, Schmid-Schönbein GW. In vivo evidence for microvascular oxidative stress in spontaneously hypertensive rats: hydroethidine microfluorography. Hypertension.. 1995;25:1083–1089.[Abstract/Free Full Text]
3. Rajagopalan S, Kurz S, Münzel T, Tarpey M, Freeman BA, Griendling KK, Harrison DG. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation: contribution to alterations of vasomotor tone. J Clin Invest.. 1996;97:1916–1923.[Medline] [Order article via Infotrieve]
4. Swei A, Lacy F, Delano FA, Schmid-Schönbein GW. Oxidative stress in the Dahl hypertensive rat. Hypertension.. 1997;30:1628–1633.[Abstract/Free Full Text]
5. Bouloumié A, Bauersachs J, Linz W, Schölkens BA, Wiemer G, Fleming I, Busse R. Endothelial dysfunction coincides with an enhanced nitric oxide synthase expression and superoxide anion production. Hypertension.. 1997;30:934–941.[Abstract/Free Full Text]
6. Ohara Y, Peterson TE, Harrison DG. Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest.. 1993;91:2546–2551.
7. White CR, Darley-Usmar V, Berrington WR, McAdams M, Gore JZ, Thompson JA, Parks DA, Tarpey MM, Freeman BA. Circulating plasma xanthine oxidase contributes to vascular dysfunction in hypercholesterolemic rabbits. Proc Natl Acad Sci U S A.. 1996;93:8745–8749.[Abstract/Free Full Text]
8. Sundaresan M, Yu ZX, Ferrans VJ, Irani K, Finkel T. Requirement for generation of H₂O₂ for platelet-derived growth factor signal transduction. Science.. 1995;270:296–299.[Abstract/Free Full Text]
9. Nishio E, Watanabe Y. The involvement of reactive oxygen species and arachidonic acid in ₁-adrenoceptor-induced smooth muscle cell proliferation and migration. Br J Pharmacol.. 1997;121:665–670.[Medline] [Order article via Infotrieve]
10. Marumo T, Schini-Kerth VB, Fisslthaler B, Busse R. Platelet-derived growth factor-stimulated superoxide anion production modulates activation of transcription factor NF-B and expression of monocyte chemoattractant protein 1 in human aortic smooth muscle cells. Circulation.. 1997;96:2361–2367.[Abstract/Free Full Text]
11. Heinecke JW, Baker L, Rosen H, Chait A. Superoxide-mediated modification of low density lipoprotein by arterial smooth muscle cells. J Clin Invest.. 1986;77:757–761.
12. Mietussnyder M, Friera A, Glass CK, Pitas RE. Regulation of scavenger receptor expression in smooth muscle cells by protein kinase C: a role for oxidative stress. Arterioscler Thromb Vasc Biol.. 1997;17:969–978.[Abstract/Free Full Text]
13. Ushio-Fukai M, Zafari AM, Fukui T, Ishizaka N, Griendling KK. p22phox is a critical component of the superoxide-generating NADH/NADPH oxidase system and regulates angiotensin II-induced hypertrophy in vascular smooth muscle cells. J Biol Chem.. 1996;271:23317–23321.[Abstract/Free Full Text]
14. Fukui T, Ishizaka N, Rajagopalan S, Lauren JB, Capers Q, Taylor WR, Harrison DG, Deleon H, Wilcox JN, Griendling KK. p22 phox mRNA expression and NADPH oxidase activity are increased in aortas from hypertensive rats. Circ Res.. 1997;80:45–51.[Abstract/Free Full Text]
15. Nashel DJ. Is atherosclerosis a complication of long-term corticosteroid treatment? Am J Med.. 1986;80:925–929.[Medline] [Order article via Infotrieve]
16. Asai K, Funaki C, Hayashi T, Yamada K, Naito M, Kuzuya M, Yoshida F, Yoshimine N, Kuzuya F. Dexamethasone-induced suppression of aortic atherosclerosis in cholesterol-fed rabbits: possible mechanisms. Arterioscler Thromb.. 1993;13:892–899.[Abstract/Free Full Text]
17. Villa AE, Guzman LA, Chen W, Golomb G, Levy RJ, Topol EJ. Local delivery of dexamethasone for prevention of neointimal proliferation in a rat model of balloon angioplasty. J Clin Invest.. 1994;93:1243–1249.
18. Scott-Burden T, Schini VB, Elizondo E, Junquero DC, Vanhoutte PM. Platelet-derived growth factor suppresses and fibroblast growth factor enhances cytokine-induced production of nitric oxide by cultured smooth muscle cells: effects on cell proliferation. Circ Res.. 1992;71:1088–1100.[Abstract/Free Full Text]
19. Ohba M, Shibanuma M, Kuroki T, Nose K. Production of hydrogen peroxide by transforming growth factor-ß₁ and its involvement in induction of egr-1 in mouse osteoblastic cells. J Cell Biol.. 1994;126:1079–1088.[Abstract/Free Full Text]
20. Zulueta JJ, Sawhney R, Yu FS, Cote CC, Hassoun PM. Intracellular generation of reactive oxygen species in endothelial cells exposed to anoxia-reoxygenation. Am J Physiol.. 1997;272:L897–L902.[Abstract/Free Full Text]
21. Crapo JD, McCord JM, Fridovich I. Preparation and assay of superoxide dismutases. Methods Enzymol.. 1978;53:382–393.[Medline] [Order article via Infotrieve]
22. Fukui T, Lassegue B, Kai H, Alexander RW, Griendling KK. Cytochrome b-558 -subunit cloning and expression in rat aortic smooth muscle cells. Biochim Biophys Acta.. 1995;1231:215–219.[Medline] [Order article via Infotrieve]
23. Marumo T, Nakaki T, Nagata K, Miyata M, Adachi H, Esumi H, Suzuki H, Saruta T, Kato R. Dexamethasone inhibits nitric oxide synthase mRNA induction by interleukin-1 and tumor necrosis factor- in vascular smooth muscle cells. Jpn J Pharmacol.. 1993;63:361–367.[Medline] [Order article via Infotrieve]
24. Speir E, Shibutani T, Yu ZX, Ferrans V, Epstein SE. Role of reactive oxygen intermediates in cytomegalovirus gene expression and in the response of human smooth muscle cells to viral infection. Circ Res.. 1996;79:1143–1152.[Abstract/Free Full Text]
25. Cathcart R, Schwiers E, Ames BN. Detection of picomole levels of hydroperoxides using a fluorescent dichlorofluorescein assay. Anal Biochem.. 1983;134:111–116.[Medline] [Order article via Infotrieve]
26. Thelen M, Dewald B, Baggiolini M. Neutrophil signal transduction and activation of the respiratory burst. Physiol Rev.. 1993;73:797–821.[Free Full Text]
27. O'Donnell VB, Smith GCM, Jones OTG. Involvement of phenyl radicals in iodonium compound inhibition of flavoenzymes. Mol Pharmacol.. 1994;46:778–785.[Abstract]
28. Amezaga MA, Bazzoni F, Sorio C, Rossi F, Cassatella MA. Evidence for the involvement of distinct signal transduction pathways in the regulation of constitutive and interferon -dependent gene expression of NADPH oxidase components (gp91-phox, p47-phox, and p22-phox) and high-affinity receptor for IgG (FcR-I) in human polymorphonuclear leukocytes. Blood.. 1992;79:735–744.[Abstract/Free Full Text]
29. Inoue N, Kawashima S, Kanazawa K, Yamada S, Akitas H, Yokoyama M. Polymorphism of the NADH/NADPH oxidase p22 phox gene in patients with coronary artery disease. Circulation.. 1998;97:135–137.[Abstract/Free Full Text]
30. Dana R, Leto TL, Malech HL, Levy R. Essential requirement of cytosolic phospholipase A₂ for activation of the phagocyte NADPH oxidase. J Biol Chem.. 1998;273:441–445.[Abstract/Free Full Text]
31. Mayer RJ, Marshall LA. New insights on mammalian phospholipase A₂(s): comparison of arachidonoyl-selective and -nonselective enzymes. FASEB J.. 1993;7:339–348.[Abstract]
32. Shibutani T, Johnson TM, Yu ZX, Ferrans VJ, Moss J, Epstein SE. Pertussis toxin-sensitive G proteins as mediators of the signal transduction pathways activated by cytomegalovirus infection of smooth muscle cells. J Clin Invest.. 1997;100:2054–2061.[Medline] [Order article via Infotrieve]
33. Graves LM, Bornfeldt KE, Sidhu JS, Argast GM, Raines EW, Ross R, Leslie CC, Krebs EG. Platelet-derived growth factor stimulates protein kinase A through a mitogen-activated protein kinase-dependent pathway in human arterial smooth muscle cells. J Biol Chem.. 1996;271:505–511.[Abstract/Free Full Text]
34. Sato A, Suzuki H, Murakami M, Nakazato Y, Iwaita Y, Saruta T. Glucocorticoid increases angiotensin II type 1 receptor and its gene expression. Hypertension.. 1994;23:25–30.[Abstract/Free Full Text]
35. Schelling JR, DeLuca DJ, Konieczkowski M, Marzec R, Sedor JR, Dubyak GR, Linas SL. Glucocorticoid uncoupling of angiotensin II-dependent phospholipase C activation in rat vascular smooth muscle cells. Kidney Int.. 1994;46:675–682.[Medline] [Order article via Infotrieve]
36. Petrichenko IE, Daret D, Kolpakova GV, Shakhov YA, Larrue J. Glucocorticoids stimulate cholesteryl ester formation in human smooth muscle cells. Arterioscler Thromb Vasc Biol.. 1997;17:1143–1151.[Abstract/Free Full Text]
37. Fishel RS, Eisenberg S, Shai-Yung S, Redden RA, Bernstein KE, Berk BC. Glucocorticoids induce angiotensin-converting enzyme expression in vascular smooth muscle. Hypertension.. 1995;25:343–349.[Abstract/Free Full Text]
38. Laurindo FR, Pedro MdA, Barbeiro HV, Pileggi F, Carvalho MH, Augusto O, da Luz PL. Vascular free radical release: ex vivo and in vivo evidence for a flow-dependent endothelial mechanism. Circ Res.. 1994;74:700–709.[Abstract/Free Full Text]
39. Hishikawa K, Lüscher TF. Pulsatile stretch stimulates superoxide production in human aortic endothelial cells. Circulation.. 1997;96:3610–3616.[Abstract/Free Full Text]
40. Graier WF, Simecek S, Kukovetz WR, Kostner GM. High D-glucose-induced changes in endothelial Ca²⁺/EDRF signaling are due to generation of superoxide anions. Diabetes.. 1996;45:1386–1395.[Abstract]
41. Pritchard KA Jr, Groszek L, Smalley DM, Sessa WC, Wu M, Villalon P, Wolin MS, Stemerman MB. Native low-density lipoprotein increases endothelial cell nitric oxide synthase generation of superoxide anion. Circ Res.. 1995;77:510–518.[Abstract/Free Full Text]

This article has been cited by other articles:

				Y. M. Kim, H. Kattach, C. Ratnatunga, R. Pillai, K. M. Channon, and B. Casadei Association of atrial nicotinamide adenine dinucleotide phosphate oxidase activity with the development of atrial fibrillation after cardiac surgery. J. Am. Coll. Cardiol., January 1, 2008; 51(1): 68 - 74. [Abstract] [Full Text] [PDF]

				R. P. Brandes Avoiding Vicious Circles: Mineralocorticoid Receptor Antagonism Prevents Vascular Oxidative Stress Early After Myocardial Infarction Hypertension, November 1, 2007; 50(5): 842 - 843. [Full Text] [PDF]

				T. Marumo, H. Uchimura, M. Hayashi, K. Hishikawa, and T. Fujita Aldosterone Impairs Bone Marrow-Derived Progenitor Cell Formation Hypertension, September 1, 2006; 48(3): 490 - 496. [Abstract] [Full Text] [PDF]

				D. D. Sin, P. Man, P. Lacy, and E. York Fluticasone Reduces CRP in COPD Am. J. Respir. Crit. Care Med., May 15, 2005; 171(10): 1191 - 1192. [Full Text] [PDF]

				B. Somoza, M. C. Gonzalez, J. M. Gonzalez, F. Abderrahim, S. M. Arribas, and M. S. Fernandez-Alfonso Modulatory role of the adventitia on noradrenaline and angiotensin II responses: Role of endothelium and AT2 receptors Cardiovasc Res, February 1, 2005; 65(2): 478 - 486. [Abstract] [Full Text] [PDF]

				M. A. Tarnopolsky, D. J. Mahoney, J. Vajsar, C. Rodriguez, T. J. Doherty, B. D. Roy, and D. Biggar Creatine monohydrate enhances strength and body composition in Duchenne muscular dystrophy Neurology, May 25, 2004; 62(10): 1771 - 1777. [Abstract] [Full Text] [PDF]

				B. Lassegue and R. E. Clempus Vascular NAD(P)H oxidases: specific features, expression, and regulation Am J Physiol Regulatory Integrative Comp Physiol, August 1, 2003; 285(2): R277 - R297. [Abstract] [Full Text] [PDF]

				T. Iuchi, M. Akaike, T. Mitsui, Y. Ohshima, Y. Shintani, H. Azuma, and T. Matsumoto Glucocorticoid Excess Induces Superoxide Production in Vascular Endothelial Cells and Elicits Vascular Endothelial Dysfunction Circ. Res., January 10, 2003; 92(1): 81 - 87. [Abstract] [Full Text] [PDF]

				P. Paredi, S. A. Kharitonov, and P. J. Barnes Analysis of Expired Air for Oxidation Products Am. J. Respir. Crit. Care Med., December 15, 2002; 166(12): S31 - 37. [Abstract] [Full Text] [PDF]

				C. D. Kim, H. K. Shin, H. S. Lee, J. H. Lee, T. H. Lee, and K. W. Hong Gene transfer of Cu/Zn SOD to cerebral vessels prevents FPI-induced CBF autoregulatory dysfunction Am J Physiol Heart Circ Physiol, May 1, 2002; 282(5): H1836 - H1842. [Abstract] [Full Text] [PDF]

				A. P. V. Dantas, R. C.A. Tostes, Z. B. Fortes, S. G. Costa, D. Nigro, and M. H. C. Carvalho In Vivo Evidence for Antioxidant Potential of Estrogen in Microvessels of Female Spontaneously Hypertensive Rats Hypertension, February 1, 2002; 39(2): 405 - 411. [Abstract] [Full Text] [PDF]

				G. Zalba, G. S. Jose, M. U. Moreno, M. A. Fortuno, A. Fortuno, F. J. Beaumont, and J. Diez Oxidative Stress in Arterial Hypertension: Role of NAD(P)H Oxidase Hypertension, December 1, 2001; 38(6): 1395 - 1399. [Abstract] [Full Text] [PDF]

				V. J. Thannickal and B. L. Fanburg Reactive oxygen species in cell signaling Am J Physiol Lung Cell Mol Physiol, December 1, 2000; 279(6): L1005 - L1028. [Abstract] [Full Text] [PDF]

				P. PAREDI, S. A. KHARITONOV, and P. J. BARNES Elevation of Exhaled Ethane Concentration in Asthma Am. J. Respir. Crit. Care Med., October 1, 2000; 162(4): 1450 - 1454. [Abstract] [Full Text] [PDF]

				P. PAREDI, S. A. KHARITONOV, D. LEAK, S. WARD, D. CRAMER, and P. J. BARNES Exhaled Ethane, a Marker of Lipid Peroxidation, Is Elevated in Chronic Obstructive Pulmonary Disease Am. J. Respir. Crit. Care Med., August 1, 2000; 162(2): 369 - 373. [Abstract] [Full Text] [PDF]

				C. Berry, C. A. Hamilton, M. J. Brosnan, F. G. Magill, G. A. Berg, J. J. V. McMurray, and A. F. Dominiczak Investigation Into the Sources of Superoxide in Human Blood Vessels : Angiotensin II Increases Superoxide Production in Human Internal Mammary Arteries Circulation, May 9, 2000; 101(18): 2206 - 2212. [Abstract] [Full Text] [PDF]

				P. PAREDI, S. A. KHARITONOV, D. LEAK, P. L. SHAH, D. CRAMER, M. E. HODSON, and P. J. BARNES Exhaled Ethane Is Elevated in Cystic Fibrosis and Correlates with Carbon Monoxide Levels and Airway Obstruction Am. J. Respir. Crit. Care Med., April 1, 2000; 161(4): 1247 - 1251. [Abstract] [Full Text]

				K. K. Griendling, D. Sorescu, and M. Ushio-Fukai NAD(P)H Oxidase : Role in Cardiovascular Biology and Disease Circ. Res., March 17, 2000; 86(5): 494 - 501. [Abstract] [Full Text] [PDF]

				S. K. WATTANAPITAYAKUL, D. M. WEINSTEIN, B. J. HOLYCROSS, and J. A. BAUER Endothelial dysfunction and peroxynitrite formation are early events in angiotensin-induced cardiovascular disorders FASEB J, February 1, 2000; 14(2): 271 - 278. [Abstract] [Full Text]

				D. N. Muller, R. Dechend, E. M. A. Mervaala, J.-K. Park, F. Schmidt, A. Fiebeler, J. Theuer, V. Breu, D. Ganten, H. Haller, et al. NF-{kappa}B Inhibition Ameliorates Angiotensin II-Induced Inflammatory Damage in Rats Hypertension, January 1, 2000; 35(1): 193 - 201. [Abstract] [Full Text] [PDF]

				P Paredi, P L Shah, P Montuschi, P Sullivan, M E Hodson, S A Kharitonov, and P J Barnes Increased carbon monoxide in exhaled air of patients with cystic fibrosis Thorax, October 1, 1999; 54(10): 917 - 920. [Abstract] [Full Text]

				A. BOULOUMIÉ, T. MARUMO, M. LAFONTAN, and R. BUSSE Leptin induces oxidative stress in human endothelial cells FASEB J, July 1, 1999; 13(10): 1231 - 1238. [Abstract] [Full Text]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services